Healthcare Business Daily News Reports that INSIGHTEC’s Exablate treatment can spare the uterus during fibroid treatment: FDA


INSIGHTEC announced on Wednesday that the FDA has approved the relabeling of the Exablate system to treat women with symptomatic uterine fibroids who want to spare their uterus and maintain fertility.

Exablate can now be used for both women who are “family complete” and those who still want to conceive.

Exablate combines focused ultrasound and MR technology to non-invasively treat uterine fibroids. High intensity focused ultrasound (HIFU) waves are used to heat and destroy the fibroid, and the MRI is used for treatment planning, real-time thermal monitoring during treatment and post-procedural assessment.

Upcoming Events

Engaging with Patients on Social Media

Restarting Incisionless Surgery in Latin America

Font Resize